Alejandra Carvajal - 03 Aug 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Chief Legal Officer
Issuer ticker: CTMX
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 19:33:34 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden, as Attorney-in-Fact for Alejandra Carvajal

Key filing fact

Alejandra Carvajal filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 05 Aug 2026.

Key facts

This page summarizes Alejandra Carvajal's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 19:33.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001645755 Primary reporting owner

Carvajal Alejandra

Relationship: Chief Legal Officer
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden, as Attorney-in-Fact for Alejandra Carvajal
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTMX transaction

Common Stock

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +450,000
Change %
Price: $0.000000^*
Shares after: 450,000
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $3.17
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.

Footnote F2

Includes 100,000 RSUs.

Footnote F3

25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.